Clinical trial
Efficacy and Safety of Addition of IL-2 to Pegylated Interferon Alpha 2a and…
NCT00196586 · French National Agency for Research on AIDS and Viral Hepatitis, Other · Completed
Key facts
| NCT number | NCT00196586 |
|---|---|
| Title | Efficacy and Safety of Addition of IL-2 to Pegylated Interferon Alpha 2a and Ribavirin in HIV/HCV Coinfected Patients |
| Official title | Pilot Study of Addition of IL-2 to Pegylated Interferon Alpha 2a and Ribavirin for the Treatment of Chronic Hepatitis C in HIV-HCV Coinfected Patients Non Responders to Three Months of Therapy With Pegylated Interferon Alpha 2a and Ribavirin. ANRS HC09 SECOIIA |
| Lead sponsor | French National Agency for Research on AIDS and Viral Hepatitis, Other |
| Collaborators | Hoffmann-La Roche Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | HIV Infections, Chronic Hepatitis C |
| Intervention type | Drug |
| Interventions | Interleukin 2, pegylated interferon alpha 2a, ribavirin |
| Enrollment | 75 |
| Start date | Apr 1, 2003 |
| Completion | Nov 1, 2006 |
| First posted | Sep 20, 2005 |
| Last update posted | Nov 16, 2007 |
| Countries | France |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: